Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease

Yuichiro Azuma; Motohiro Tamiya; Takayuki Shiroyama; Akio Osa; Sawa Takeoka; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Tomonori Hirashima; Ichiro Kawase

doi:10.2169/internalmedicine.54.3243

CASE REPORTS

Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease

Yuichiro Azuma, Motohiro Tamiya, Takayuki Shiroyama, Akio Osa, Sawa Takeoka, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Tomonori Hirashima, Ichiro Kawase

Author information

Yuichiro Azuma
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Motohiro Tamiya
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Takayuki Shiroyama
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Akio Osa
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Sawa Takeoka
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Naoko Morishita
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Hidekazu Suzuki
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Norio Okamoto
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Tomonori Hirashima
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
Ichiro Kawase
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan

Keywords: nab-paclitaxel, SCLC, interstitial lung disease, chemotherapy

JOURNAL OPEN ACCESS

2015 Volume 54 Issue 22 Pages 2911-2913

DOI https://doi.org/10.2169/internalmedicine.54.3243

Details

Abstract

It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.

Corresponding author

Register with J-STAGE for free!